BioStock: SynAct Pharma’s CEO comments on EXPAND data
SynAct Pharma has announced disappointing top-line data from its 12-week EXPAND phase IIb clinical trial. The study is evaluating the drug candidate resomelagon in newly diagnosed rheumatoid arthritis patients with severe disease. Results show a high placebo effect thus not achieving the primary endpoint – a statistically higher rate of 20 improvement in the American College of Rheumatology score compared to placebo. BioStock spoke to CEO Torbjørn Bjerke about the results.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/synact-pharmas-ceo-comments-on-expand-data/